Q&A with Steven Lydeamore, CEO of Immuron Limited
Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream.
https://www.immuron.com.au/assets/files/Profiled%20Company%20-%20Immuron%20-%20Summer%202023%20Issue.pdf
Filter by Year:
- Innovation begins with collaboration: Steven Lydeamore
- Immuron hails record monthly sales of Travelan
- Immuron working towards US FDA approval of Traveler’s Diarrhea product Travelan
- Immuron Sees Substantial Sales Growth in FY23 Driven by Resurgence in Travel (ASX:IMC)
- Immuron Limited CEO Steven Lydeamore interview with Stuart Roberts Management Interview Series – Stocks Down Under
- Q&A with Steven Lydeamore, CEO of Immuron Limited
- Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission
- Clinical data imminent!
- Immuron grows revenue by 153% in H1 FY23 with more growth catalysts lined up
- Sequire Spotlight Presents Immuron Limited (IMRN): Creating New Products for Infectious Diseases
- Immuron Limited Announces Participation in the LD Micro Invitational XIII
- Beating bacteria just got boosted
- US recruitment milestone for trial of Immuron's Travelan
- Immuron on How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
